A novel blood test for calcification propensity was associated with cardiovascular mortality among patients with ischemic heart failure with reduced ejection fraction (HFrEF). These findings from a retrospective study were published in Frontiers in Medicine.
Patients (N=306) with HFrEF were recruited for this study between 2008 and 2013 at the Medical University of Vienna in Vienna, Austria. Laboratory measurements, including the calcification propensity score (T50) that assesses the half-maximum transition time from primary to secondary formation of protein-mineral calciprotein particle complexes, were related with 2-year mortality.
Stratified by tertiles of T50, patients in the low, intermediate, and high tertiles differed significantly for phosphate (median, 1.19 vs 1.06 vs 0.97 mmol/L; P <.001), intact fibroblast growth factor-23 (median, 69.05 vs 63.50 vs 62.50 pg/mL; P =.021), and albumin (median, 42.80 vs 43.90 vs 44.30 g/L; P =.024) concentrations.
During the median follow-up of 3.2 years, 37.3% (n=114) had died, and 24.8% (N=76) had cardiovascular-related mortality.
Patients with lower T50 tertiles, or high calcification propensity, had increased rates of all-cause (P =.036) and cardiovascular-related (P =.04) mortality. This trend was not observed among all T50 tertiles (P =.095; P =.434, respectively).
Stratified by ischemic and nonischemic HFrEF, lower T50 was associated with increased cardiovascular-related mortality (P =.011) among the ischemic cohort but not the nonischemic group (P =.978). The association between cardiovascular mortality and ischemic HFrEF remained significant in the fully adjusted model (subhazard ratio, 0.65; 95% CI, 0.45-0.93; P =.019).
This study was limited by its retrospective design and by the fact that patients were assessed for T50 on a single occasion at baseline. It remains unclear whether T50 varies over time or whether any variation in calcification propensity affects clinical outcomes.
These data indicate the novel blood test for calcification propensity, T50, is associated with cardiovascular mortality among patients with ischemic HFrEF. Additional studies are needed to confirm these findings.
Bojic M, Koller L, Cejka D, Niessner A, Bielesz B. Propensity for calcification in serum associates with 2-year cardiovascular mortality in ischemic heart failure with reduced ejection fraction. Front Med (Lausanne). 2021;8:672348. doi:10.3389/fmed.2021.672348